The regulator said on Friday that the Food and Drug Administration plans to finalize and issue emergency use authorization for the biotech PNTX, + 5.48% and Pfizer Inc. PFE, -0.29% test Covit-19 vaccine. Shares of Bioendech rose 1.5% in early trading on Friday, while Pfizer rose 2.1%. The announcement comes a day after a federal advisory panel of independent medical experts voted 17-4-1 that the benefits of the vaccine outweigh the risks, which is seen as the final step in the U.S. regulatory process before the FDA decides whether to grant it. Emergency use authorization for the COVID-19 vaccine candidate. The FDA is not required to follow the panel’s recommendation, but often does. The FDA said it was also in touch with the Centers for Disease Control and Prevention and Operation Warp Speed, which are set up to develop treatments and vaccines during infections, so “so they can implement their plans for timely vaccine distribution.” If the vaccine is approved, it will be the first COVID-19 vaccine available to Americans outside of clinical trials. .
Source